Pipeline

NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. The development stage of NeuClone’s eight publicly disclosed biosimilar products are outlined below.

ORIGINATOR

Stelara®
Ustekinumab

Herceptin®
Trastuzumab

Perjeta®
Pertuzumab

Prolia®/Xgeva®

Denosumab

Keytruda®

Pembrolizumab

Synagis®

Palivizumab

Opdivo®

Nivolumab

Humira®

Adalimumab

EARLY PRECLINICAL

LATE PRECLINICAL

PROCESS SCALE-UP

PHASE I

PHASE III

12 other products in development.

Herceptin
Trastuzumab

Early Preclinical

Late Preclinical

Process Scale-up

Phase 1 – 2018

Stelara
Ustekinumab

Early Preclinical

Late Preclinical

Process Scale-up

Phase 1 – 2019

Prolia/XGEVA
Denosumab

Early Preclinical

Late Preclinical

Process Scale-up

Synagis
Palivizumab

Early Preclinical

Late Preclinical

Process Scale-up

Perjeta
Pertuzumab

Early Preclinical

Late Preclinical

Process Scale-up

Opdivo
Nivolumab

Early Preclinical

Late Preclinical

Process Scale-up

Keytruda
Pembrolizumab

Early Preclinical

Late Preclinical

Process Scale-up

Humira
Adalimumab

Early Preclinical

Late Preclinical

Learn more about what we do

Download NeuClone Brochure

 

Ellipse2_background-01